Revenue reached $123.1M in Q3 2026 with gross margin of 69.9%, yet operating margin of -8.5% and GAAP net loss of -$12.3M show that operating leverage has not yet turned the business profitable.
GeneDx Holdings Corp. (WGS) annual income statement — 6-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 |
|---|
| Sales/Revenue | 460.78M | 427.54M | 305.45M | 202.57M | 234.69M | 212.19M | 179.32M |
| Revenue Growth % | 14.57% | 39.97% | 50.79% | -13.69% | 10.6% | 18.33% | - |
| Cost of Goods Sold | 149.35M | 129.37M | 111.05M | 112.56M | 261.44M | 228.8M | 175.3M |
| COGS % of Revenue | - | 30.26% | 36.36% | 55.57% | 111.4% | 107.82% | 97.75% |
| Gross Profit | 311.43M | 298.17M | 194.4M | 90.01M | -26.75M | -16.6M | 4.03M |
| Gross Margin % | 67.59% | 69.74% | 63.64% | 44.43% | -11.4% | -7.82% | 2.25% |
| Gross Profit Growth % | - | 53.38% | 115.98% | 436.47% | -61.13% | -512.37% | - |
| Operating Expenses | 379.22M | 311.25M | 217.61M | 270.6M | 640.9M | 429.55M | 246.02M |
| OpEx % of Revenue | - | 72.8% | 71.24% | 133.59% | 273.08% | 202.43% | 137.19% |
| Selling, General & Admin | 304.19M | 239.22M | 168.48M | 194.71M | 338.24M | 318.73M | 163.93M |
| SG&A % of Revenue | - | 55.95% | 55.16% | 96.12% | 144.12% | 150.2% | 91.41% |
| Research & Development | 80.86M | 72.03M | 45.72M | 58.27M | 86.2M | 105.16M | 72.7M |
| R&D % of Revenue | - | 16.85% | 14.97% | 28.76% | 36.73% | 49.56% | 40.54% |
| Other Operating Expenses | -1000K | 0 | 3.41M | 17.63M | 216.46M | 5.66M | 9.39M |
| Operating Income | -67.79M | -11.8M | -23.21M | -180.6M | -667.65M | -446.15M | -241.99M |
| Operating Margin % | -14.71% | -2.76% | -7.6% | -89.15% | -284.48% | -210.25% | -134.95% |
| Operating Income Growth % | - | 49.16% | 87.15% | 72.95% | -49.65% | -84.36% | - |
| EBITDA | -40.49M | 13.42M | -1.26M | -146.86M | -608.34M | -424.34M | -230.26M |
| EBITDA Margin % | -8.79% | 3.14% | -0.41% | -72.5% | -259.21% | -199.98% | -128.41% |
| EBITDA Growth % | -219.55% | 1165.24% | 99.14% | 75.86% | -43.36% | -84.29% | - |
| D&A (Non-Cash Add-back) | 27.3M | 25.22M | 21.95M | 33.73M | 59.31M | 21.81M | 11.73M |
| EBIT | -107.01M | -18.6M | -49.6M | -170.19M | -457.51M | -242.56M | -238.87M |
| Net Interest Income | -4.2M | -2.54M | -3.03M | 1.11M | -666K | -2.76M | -1.97M |
| Interest Income | 0 | 0 | 0 | 1.11M | 2.54M | 79K | 506K |
| Interest Expense | 4.2M | 2.54M | 3.03M | 0 | 3.21M | 2.83M | 2.47M |
| Other Income/Expense | -43.42M | -9.34M | -29.42M | 3.9M | 69.62M | 200.76M | 654K |
| Pretax Income | -111.21M | -21.14M | -52.63M | -176.69M | -598.03M | -245.39M | -241.34M |
| Pretax Margin % | -24.13% | -4.94% | -17.23% | -87.23% | -254.81% | -115.64% | -134.58% |
| Income Tax | 877K | -116K | -343K | -926K | -49.05M | 0 | 0 |
| Effective Tax Rate % | -0.79% | 0.55% | 0.65% | 0.52% | 8.2% | 0% | 0% |
| Net Income | -111.05M | -21.02M | -52.29M | -175.77M | -548.98M | -245.39M | -241.34M |
| Net Margin % | -24.1% | -4.92% | -17.12% | -86.77% | -233.91% | -115.64% | -134.58% |
| Net Income Growth % | -5431.2% | 59.8% | 70.25% | 67.98% | -123.72% | -1.68% | - |
| Net Income (Continuing) | -112.08M | -21.02M | -52.29M | -175.77M | -548.98M | -245.39M | -241.34M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -3.72 | -0.73 | -1.94 | -7.23 | -53.63 | -74.93 | -146.94 |
| EPS Growth % | -6366.67% | 62.37% | 73.17% | 86.52% | 28.43% | 49.01% | - |
| EPS (Basic) | - | -0.73 | -1.94 | -7.23 | -53.63 | -74.93 | -33.16 |
| Diluted Shares Outstanding | 29.88M | 26.89M | 26.89M | 24.31M | 10.24M | 3.28M | 5.63M |
| Basic Shares Outstanding | 29.88M | 26.89M | 26.89M | 24.31M | 10.24M | 3.28M | 5.63M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying WGS stock.
For fiscal year 2025, GeneDx Holdings Corp. (WGS) reported total revenue of $427.5M. This represents a 138.4% increase compared to $179.3M in 2020.
GeneDx Holdings Corp. (WGS) reported a net loss of $21.0M for the fiscal year ending 2025.
GeneDx Holdings Corp. (WGS) reported an operating income of $-11.8M, resulting in an operating profit margin of -2.8%. This margin reflects the operational efficiency of the business before interest and taxes.
GeneDx Holdings Corp. (WGS) generated $298.2M in gross profit for the year, representing a gross profit margin of 69.7%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Persistent GAAP losses and regulatory overhang
Metrics are mathematically derived from official filings.
Revenue Growth Sustained Across Eight Quarters
According to reported quarterly figures, WGS grew revenue from $70.5M in Q2 2024 to $123.1M in Q3 2026, with year-over-year growth of 5.4% in the latest quarter signaling deceleration from earlier 40-plus percent rates.
The sharp deceleration to 5.4% year-over-year in Q3 2026, after 40-66% comparisons through 2025, suggests the easy base effects that drove the early inflection are fading. Sequential growth from $114.4M to $123.1M is encouraging, but investors should monitor whether exome and genome volume growth can sustain high-single-digit or better rates as comparisons harden. The data does not isolate volume versus pricing contributions, so the durability of ASP gains remains unverified.
Gross Margin Recovery Lacks Pricing Confirmation
Based on reported figures, gross margin expanded from 60.9% in Q2 2024 to roughly 69.9% in Q3 2026, a level that compares favorably with the 64.8% gross margin of peer Natera.
The roughly nine-point gross margin improvement is consistent with a mix shift toward higher-complexity testing and better lab throughput, though the filings supplied do not separate these drivers. Gross margin dipped to 65.2% in Q4 2025 before recovering, indicating the figure is sensitive to quarterly revenue adjustments and COGS timing. Sustaining near-70% margins will depend on whether reimbursement rates hold against payer pressure.
Operating Leverage Emerging but Not Yet Positive
As reported in the income statement, operating loss narrowed from -$17.5M in Q2 2026 to -$10.4M in Q3 2026 as SG&A held near $79M, implying partial operating leverage on a revenue base still below breakeven.
Operating margin improved from -25.6% in Q1 2026 to -8.5% in Q3 2026, suggesting that incremental gross profit is outpacing overhead growth. SG&A remains very high relative to revenue at roughly 64% of sales, so margin expansion depends heavily on continued top-line growth without proportional cost increases. Investors should watch whether SG&A growth stays flat as revenue scales toward the $135M full-year guidance.
Net Income Volatility Obscures Underlying Trend
Based on reported figures, net income swung from a -$63.3M loss in Q1 2026 to a -$12.3M loss in Q3 2026, with EPS volatility reflecting one-time items and a per-share figure that remains unverified in the source data.
The gap between operating loss and net loss in several quarters, including Q1 2026 where net loss was more than double the operating loss, suggests non-operating or discontinued-operations items that warrant further investigation. Stock-based compensation of $8.3M in Q3 2026 is a meaningful share of revenue and inflates the cost base relative to cash operating performance. Adjusted net income guidance of roughly $12M for the full year is non-GAAP, so investors should reconcile it against GAAP results before relying on it.
Guidance Implies Sharp Profitability Step-Up
Based on reported guidance, full-year 2026 adjusted net income of roughly $12M against Q3 GAAP net loss of -$12.3M implies a substantial fourth-quarter swing that warrants skepticism about execution.
The guided profit inflection requires a quarter-over-quarter improvement well beyond the trajectory seen in recent quarters, and the operating margin of -8.5% in Q3 remains negative. Bears would argue that adjusted metrics exclude recurring costs such as stock compensation and restructuring, flattering the apparent progress. Proposed FDA oversight of laboratory developed tests could also raise compliance costs and delay launches, pressuring margins if the regulatory path materializes.